A Phase 3 interventional study of Low molecular weight heparin and Placebos in Intrauterine Growth Restriction, sponsored by Fundació Sant Joan de Déu. Completed at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-22.
Sponsored by Fundació Sant Joan de Déu · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Fetal Growth Retardation with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Fetal Growth Retardation · Spain.
Among the 18 studies in Fetal Growth Retardation with a site in Spain, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 3, and was the 7th registered.
262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.
Browse Fetal Growth Retardation studies →7 of the 18 studies in Fetal Growth Retardation with a site in Spain are open now. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18+ · Women only
Aristotle University Of Thessaloniki · Sites in Spain, Bulgaria, Greece
Ages 18+ · Women only · Healthy volunteers
Leiden University Medical Center · Sites in Spain, United States, Belgium and 3 more countries
Ages 18–50
Institut d'Investigacions Biomèdiques August Pi i Sunyer · Sites in Spain
Ages 18+ · Women only
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain, Belgium, Colombia and 6 more countries
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.
Median enrollment 340 across the 11 interventional studies, 274 across the 7 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
Fundació Sant Joan de Déu is the lead sponsor of 72 studies on the registry; 21 are open to participants now.
Fundació Sant Joan de Déu has 1 study filed under Fetal Growth Retardation — fewer than ten, so there is no comparison to draw.
3 of the studies in Fetal Growth Retardation with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04766866Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauSFlt1/PlGF and Planned Delivery to Prevent Preeclampsia At Term. | 2026-12-31 |
| NCT02297724Boston Children's HospitalMRI Assessment of Placental Health | 2027-09 |
| NCT07098975Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauStatin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial) | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Fetal Growth Retardation with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TREATMENT OF INTRAUTERINE GROWTH RESTRICTION WITH LOW MOLECULAR WEIGHT HEPARIN.
TREATMENT OF INTRAUTERINE GROWTH RESTRICTION WITH LOW MOLECULAR WEIGHT HEPARIN: RANDOMIZED CLINICAL TRIAL (TRACIP STUDY).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with low molecular weight Heparin.
Drug: Low molecular weight heparin
Treatment with Placebo.
Drug: Placebos
Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
Also known as: heparin
Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
Also known as: sodium chloride (0.9%)
Efficacy of low molecular weight heparin in the prolongation of gestation.
Measured as gestational age (weeks) at birth (dated by ultrasonography \<14 weeks by measurement of caudal skull length).
Time frame: 13 weeks maximum
Efficacy of low molecular weight heparin in reducing neonatal morbidity
Measured as the presence of one or more of the following: Perinatal mortality (\> 22 weeks of gestation - \<28 days postpartum), Significant neonatal morbidity (convulsions, intraventricular haemorrhage\> grade III, periventricular leukomalacia, hypoxic-ischemic encephalopathy, abnormal electroencephalogram, necrotizing enterocolitis, acute renal failure (serum creatinine\> 1.5 mg / dL) or cardiac failure (requiring inotropic agents), Perinatal mortality (22 weeks to 28 postnatal days), Biomarkers.
Time frame: 13 weeks maximum
Demonstrate that low molecular weight heparin improves the pro-angiogenic and anti-inflammatory profile.
Measured as the presence of one or more of the following: mother blood biomarkers (sFlt and PlGF), biomerkers, umbilical cord blood biomarkers (TNF alfa, IL6, IFN gamma, FGF basic, VEGF and PlGF), mRNA in trophoblast.( IL6, INFg, TNF alfa, VEGFA, VEGFB, FGF2 y RQVEGF).
Time frame: 13 weeks maximum
Efficacy of low molecular weight heparin in reducing thrombotic and ischemic placental lesions
Measured as the presence of one or more of the following: Intrauterine growth retardation (Neonatal weight below the 10th percentile of our population + umbilical artery pulsatility index during the third trimester (on two separate occasions\> 48h) above the 95th percentile), Preeclampsia, Gestational age (weeks) at birth, Premature delivery before 34 weeks of gestation, Urgent cesarean section due to loss of fetal well-being, Neonatal weight, Neonatal acidosis (arterial pH \<7.10 + EB\> 12mEq / L), Days stay in the Neonatal Intensive Care Unit, mRNA in trophoblast.
Time frame: 13 weeks maximum
Plan to share: No
Ran from Jan 2018 to primary completion in Apr 2022, 51 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Heparin, Low-Molecular-Weight
Fundació Sant Joan de Déu